| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 100 | 2026 | 1131 | 18.720 |
Why?
|
| Tissue and Organ Procurement | 38 | 2026 | 253 | 10.810 |
Why?
|
| Waiting Lists | 36 | 2026 | 242 | 9.390 |
Why?
|
| Tissue Donors | 36 | 2025 | 502 | 8.780 |
Why?
|
| Kidney Transplantation | 20 | 2026 | 572 | 7.530 |
Why?
|
| End Stage Liver Disease | 27 | 2025 | 189 | 7.130 |
Why?
|
| Graft Rejection | 21 | 2026 | 560 | 6.300 |
Why?
|
| Graft Survival | 38 | 2025 | 466 | 5.900 |
Why?
|
| Organ Transplantation | 12 | 2025 | 172 | 4.180 |
Why?
|
| Lung Transplantation | 8 | 2026 | 350 | 3.780 |
Why?
|
| Retrospective Studies | 96 | 2026 | 17667 | 3.200 |
Why?
|
| Heart Transplantation | 10 | 2025 | 832 | 3.120 |
Why?
|
| Transplant Recipients | 12 | 2025 | 234 | 3.050 |
Why?
|
| Length of Stay | 10 | 2025 | 1399 | 3.000 |
Why?
|
| Risk Factors | 57 | 2026 | 10959 | 2.880 |
Why?
|
| Donor Selection | 9 | 2024 | 58 | 2.740 |
Why?
|
| Liver Neoplasms | 25 | 2025 | 1387 | 2.470 |
Why?
|
| Allografts | 17 | 2025 | 209 | 2.370 |
Why?
|
| Liver Failure | 6 | 2017 | 90 | 2.230 |
Why?
|
| Registries | 11 | 2025 | 1599 | 1.890 |
Why?
|
| Humans | 164 | 2026 | 131671 | 1.770 |
Why?
|
| Carcinoma, Hepatocellular | 18 | 2025 | 998 | 1.760 |
Why?
|
| Child, Preschool | 43 | 2026 | 15057 | 1.710 |
Why?
|
| Adolescent | 51 | 2026 | 20982 | 1.680 |
Why?
|
| Survival Rate | 19 | 2022 | 2151 | 1.660 |
Why?
|
| Child | 55 | 2026 | 26299 | 1.600 |
Why?
|
| Infant | 39 | 2026 | 13306 | 1.530 |
Why?
|
| Male | 93 | 2026 | 65264 | 1.520 |
Why?
|
| Female | 87 | 2026 | 71181 | 1.410 |
Why?
|
| Adult | 57 | 2026 | 31717 | 1.310 |
Why?
|
| Intention to Treat Analysis | 3 | 2024 | 61 | 1.210 |
Why?
|
| Middle Aged | 51 | 2026 | 28886 | 1.190 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 313 | 1.180 |
Why?
|
| Prognosis | 19 | 2026 | 4952 | 1.150 |
Why?
|
| Reoperation | 4 | 2024 | 844 | 1.150 |
Why?
|
| Age Factors | 10 | 2025 | 2872 | 1.130 |
Why?
|
| United States | 35 | 2026 | 11802 | 1.110 |
Why?
|
| Drug Overdose | 2 | 2020 | 72 | 1.100 |
Why?
|
| Treatment Outcome | 38 | 2025 | 12984 | 1.100 |
Why?
|
| Follow-Up Studies | 25 | 2026 | 5297 | 1.100 |
Why?
|
| Databases, Factual | 11 | 2026 | 1224 | 1.080 |
Why?
|
| Decision Support Techniques | 4 | 2019 | 298 | 1.050 |
Why?
|
| Creatinine | 3 | 2025 | 402 | 1.050 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2026 | 1078 | 1.030 |
Why?
|
| Hypernatremia | 2 | 2024 | 32 | 1.020 |
Why?
|
| Time Factors | 15 | 2026 | 6279 | 1.010 |
Why?
|
| Hepatoblastoma | 4 | 2023 | 187 | 1.010 |
Why?
|
| Risk Assessment | 12 | 2026 | 3695 | 0.960 |
Why?
|
| Severity of Illness Index | 16 | 2025 | 3101 | 0.960 |
Why?
|
| Living Donors | 8 | 2024 | 116 | 0.930 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2023 | 61 | 0.910 |
Why?
|
| Postoperative Complications | 13 | 2025 | 3130 | 0.900 |
Why?
|
| Cold Ischemia | 3 | 2024 | 28 | 0.870 |
Why?
|
| Liver Cirrhosis | 11 | 2025 | 901 | 0.820 |
Why?
|
| Liver | 12 | 2025 | 1799 | 0.810 |
Why?
|
| Kidney Failure, Chronic | 6 | 2024 | 943 | 0.810 |
Why?
|
| Multivariate Analysis | 10 | 2025 | 1405 | 0.800 |
Why?
|
| Schools | 1 | 2025 | 240 | 0.800 |
Why?
|
| Urban Population | 1 | 2025 | 281 | 0.800 |
Why?
|
| Healthcare Disparities | 4 | 2021 | 506 | 0.800 |
Why?
|
| Pancreas Transplantation | 1 | 2023 | 30 | 0.800 |
Why?
|
| Kidney Diseases | 2 | 2026 | 482 | 0.790 |
Why?
|
| Biliary Atresia | 3 | 2025 | 220 | 0.780 |
Why?
|
| Transplantation | 2 | 2019 | 26 | 0.770 |
Why?
|
| Rural Population | 1 | 2025 | 260 | 0.770 |
Why?
|
| Proportional Hazards Models | 10 | 2025 | 1405 | 0.770 |
Why?
|
| Health Facilities | 2 | 2019 | 68 | 0.730 |
Why?
|
| Logistic Models | 7 | 2024 | 1831 | 0.720 |
Why?
|
| Models, Theoretical | 2 | 2015 | 366 | 0.720 |
Why?
|
| Young Adult | 22 | 2025 | 10104 | 0.710 |
Why?
|
| Aged | 27 | 2025 | 21256 | 0.680 |
Why?
|
| Cystic Fibrosis | 2 | 2020 | 267 | 0.640 |
Why?
|
| Blood Group Incompatibility | 3 | 2018 | 27 | 0.640 |
Why?
|
| ABO Blood-Group System | 3 | 2018 | 60 | 0.630 |
Why?
|
| Learning Curve | 1 | 2020 | 58 | 0.620 |
Why?
|
| Hospitalization | 3 | 2020 | 1939 | 0.610 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2017 | 90 | 0.600 |
Why?
|
| Infant, Newborn | 16 | 2024 | 8589 | 0.600 |
Why?
|
| Alcohol Abstinence | 1 | 2019 | 15 | 0.590 |
Why?
|
| Machine Learning | 1 | 2023 | 375 | 0.590 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2018 | 40 | 0.590 |
Why?
|
| Immunosuppressive Agents | 7 | 2026 | 667 | 0.580 |
Why?
|
| Liver Diseases | 3 | 2022 | 381 | 0.580 |
Why?
|
| Acute Disease | 4 | 2026 | 1153 | 0.570 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 670 | 0.560 |
Why?
|
| Survival Analysis | 12 | 2021 | 1521 | 0.550 |
Why?
|
| Critical Care | 3 | 2021 | 680 | 0.550 |
Why?
|
| Portal Vein | 3 | 2018 | 88 | 0.540 |
Why?
|
| Suicide | 1 | 2020 | 206 | 0.520 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 34 | 0.510 |
Why?
|
| Narcotics | 1 | 2017 | 59 | 0.510 |
Why?
|
| Malnutrition | 1 | 2019 | 156 | 0.500 |
Why?
|
| Blood Loss, Surgical | 2 | 2019 | 169 | 0.500 |
Why?
|
| Alcoholism | 1 | 2019 | 246 | 0.490 |
Why?
|
| Kidney | 6 | 2023 | 1309 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 1277 | 0.460 |
Why?
|
| Quality Improvement | 1 | 2021 | 707 | 0.460 |
Why?
|
| Quality of Life | 1 | 2025 | 2117 | 0.460 |
Why?
|
| Patient Selection | 6 | 2020 | 726 | 0.460 |
Why?
|
| Neoadjuvant Therapy | 5 | 2025 | 407 | 0.450 |
Why?
|
| Models, Statistical | 1 | 2017 | 493 | 0.440 |
Why?
|
| Endpoint Determination | 1 | 2015 | 56 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 775 | 0.430 |
Why?
|
| Cause of Death | 4 | 2019 | 510 | 0.430 |
Why?
|
| Medical Futility | 1 | 2014 | 41 | 0.420 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 890 | 0.410 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2023 | 713 | 0.410 |
Why?
|
| Sodium | 4 | 2024 | 281 | 0.400 |
Why?
|
| Cohort Studies | 8 | 2026 | 5123 | 0.390 |
Why?
|
| HLA Antigens | 2 | 2025 | 229 | 0.390 |
Why?
|
| Predictive Value of Tests | 5 | 2025 | 2297 | 0.380 |
Why?
|
| Hyponatremia | 2 | 2024 | 74 | 0.370 |
Why?
|
| Hepatectomy | 1 | 2013 | 124 | 0.370 |
Why?
|
| Glomerular Filtration Rate | 5 | 2025 | 567 | 0.360 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 104 | 0.350 |
Why?
|
| Heart Failure | 3 | 2020 | 2307 | 0.350 |
Why?
|
| Altruism | 2 | 2010 | 24 | 0.350 |
Why?
|
| ROC Curve | 2 | 2025 | 615 | 0.350 |
Why?
|
| Blood Transfusion | 1 | 2013 | 290 | 0.340 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 126 | 0.330 |
Why?
|
| Vascular Grafting | 3 | 2019 | 48 | 0.310 |
Why?
|
| Perioperative Care | 3 | 2021 | 215 | 0.310 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2022 | 404 | 0.310 |
Why?
|
| Ablation Techniques | 2 | 2020 | 31 | 0.300 |
Why?
|
| Acute-On-Chronic Liver Failure | 2 | 2021 | 72 | 0.300 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 697 | 0.300 |
Why?
|
| Hepatitis C | 2 | 2023 | 390 | 0.290 |
Why?
|
| Bile Duct Neoplasms | 2 | 2025 | 131 | 0.290 |
Why?
|
| Hepatitis C, Chronic | 2 | 2023 | 367 | 0.280 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2008 | 14 | 0.280 |
Why?
|
| Pyelonephritis | 1 | 2008 | 29 | 0.270 |
Why?
|
| Embolism, Air | 1 | 2008 | 22 | 0.270 |
Why?
|
| Lithotripsy | 1 | 2008 | 29 | 0.270 |
Why?
|
| Gift Giving | 1 | 2008 | 18 | 0.270 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2020 | 218 | 0.270 |
Why?
|
| Organ Preservation | 2 | 2025 | 60 | 0.260 |
Why?
|
| HIV | 2 | 2025 | 179 | 0.250 |
Why?
|
| Perfusion | 2 | 2025 | 210 | 0.250 |
Why?
|
| Geography | 2 | 2018 | 119 | 0.250 |
Why?
|
| Death | 2 | 2020 | 77 | 0.250 |
Why?
|
| Erythrocyte Transfusion | 3 | 2019 | 142 | 0.250 |
Why?
|
| Reperfusion Injury | 2 | 2025 | 109 | 0.240 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2013 | 28 | 0.240 |
Why?
|
| Klatskin Tumor | 1 | 2025 | 10 | 0.240 |
Why?
|
| Cyclosporine | 1 | 2026 | 129 | 0.230 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 3834 | 0.230 |
Why?
|
| Sirolimus | 2 | 2025 | 231 | 0.230 |
Why?
|
| Karnofsky Performance Status | 1 | 2024 | 13 | 0.230 |
Why?
|
| Esophageal and Gastric Varices | 3 | 2025 | 74 | 0.220 |
Why?
|
| Odds Ratio | 2 | 2021 | 1235 | 0.220 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 910 | 0.210 |
Why?
|
| Cholestasis | 1 | 2025 | 165 | 0.200 |
Why?
|
| Health Care Rationing | 2 | 2021 | 59 | 0.200 |
Why?
|
| Sex Factors | 2 | 2025 | 1346 | 0.200 |
Why?
|
| Histocompatibility Testing | 1 | 2023 | 109 | 0.200 |
Why?
|
| Health Policy | 1 | 2025 | 227 | 0.190 |
Why?
|
| Postoperative Period | 2 | 2020 | 335 | 0.190 |
Why?
|
| Alcohol Drinking | 2 | 2023 | 348 | 0.190 |
Why?
|
| Hemochromatosis | 1 | 2022 | 39 | 0.180 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 33 | 0.180 |
Why?
|
| Iliac Vein | 2 | 2019 | 28 | 0.180 |
Why?
|
| HIV Infections | 2 | 2025 | 2037 | 0.180 |
Why?
|
| Bayes Theorem | 1 | 2023 | 306 | 0.180 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 49 | 0.170 |
Why?
|
| Stroke Volume | 1 | 2024 | 531 | 0.170 |
Why?
|
| Transplants | 1 | 2021 | 38 | 0.170 |
Why?
|
| United Kingdom | 2 | 2019 | 255 | 0.170 |
Why?
|
| Aftercare | 2 | 2019 | 154 | 0.170 |
Why?
|
| Coinfection | 1 | 2023 | 192 | 0.170 |
Why?
|
| Protective Factors | 1 | 2021 | 93 | 0.170 |
Why?
|
| Fatty Liver | 2 | 2013 | 220 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 501 | 0.160 |
Why?
|
| Thrombosis | 2 | 2022 | 495 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2025 | 225 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 143 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2024 | 547 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2023 | 400 | 0.160 |
Why?
|
| Biomarkers | 3 | 2025 | 3405 | 0.150 |
Why?
|
| Epidemics | 1 | 2020 | 58 | 0.150 |
Why?
|
| Chickenpox Vaccine | 1 | 2019 | 14 | 0.150 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2019 | 14 | 0.150 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2019 | 41 | 0.150 |
Why?
|
| Linear Models | 3 | 2018 | 695 | 0.150 |
Why?
|
| Pandemics | 3 | 2023 | 1164 | 0.150 |
Why?
|
| Operative Time | 3 | 2019 | 205 | 0.150 |
Why?
|
| Rituximab | 1 | 2020 | 174 | 0.150 |
Why?
|
| Hepatic Artery | 1 | 2019 | 47 | 0.150 |
Why?
|
| Eligibility Determination | 1 | 2019 | 36 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2021 | 215 | 0.150 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 1260 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2020 | 192 | 0.140 |
Why?
|
| Iliac Artery | 1 | 2019 | 63 | 0.140 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 99 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 207 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 313 | 0.140 |
Why?
|
| Celiac Artery | 1 | 2018 | 31 | 0.140 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 139 | 0.140 |
Why?
|
| Hypertension, Portal | 1 | 2018 | 79 | 0.140 |
Why?
|
| Incidence | 5 | 2019 | 3347 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2021 | 278 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 87 | 0.130 |
Why?
|
| Cystatin C | 1 | 2018 | 71 | 0.130 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2017 | 8 | 0.130 |
Why?
|
| Ectodermal Dysplasia | 1 | 2017 | 47 | 0.130 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 51 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 156 | 0.130 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 232 | 0.130 |
Why?
|
| Emergencies | 1 | 2018 | 180 | 0.130 |
Why?
|
| Calcineurin Inhibitors | 1 | 2017 | 22 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2017 | 75 | 0.130 |
Why?
|
| Everolimus | 1 | 2017 | 48 | 0.130 |
Why?
|
| Critical Illness | 2 | 2021 | 615 | 0.130 |
Why?
|
| Drowning | 1 | 2017 | 47 | 0.120 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 686 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2143 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2023 | 952 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2019 | 506 | 0.120 |
Why?
|
| Disease Progression | 4 | 2025 | 2206 | 0.120 |
Why?
|
| Hospitals | 1 | 2018 | 445 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 1745 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 252 | 0.110 |
Why?
|
| Craniosynostoses | 1 | 2017 | 156 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2017 | 305 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 366 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2989 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2018 | 305 | 0.110 |
Why?
|
| Risk | 1 | 2016 | 739 | 0.110 |
Why?
|
| Lung | 1 | 2022 | 1565 | 0.110 |
Why?
|
| California | 1 | 2014 | 128 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2017 | 517 | 0.100 |
Why?
|
| Metabolomics | 1 | 2017 | 493 | 0.100 |
Why?
|
| Ascites | 2 | 2025 | 99 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6922 | 0.100 |
Why?
|
| Validation Studies as Topic | 1 | 2013 | 12 | 0.100 |
Why?
|
| Hepatic Encephalopathy | 2 | 2025 | 82 | 0.100 |
Why?
|
| Pathology, Surgical | 1 | 2013 | 16 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1617 | 0.100 |
Why?
|
| Transfusion Reaction | 1 | 2013 | 42 | 0.100 |
Why?
|
| Pancreatitis, Chronic | 1 | 2013 | 82 | 0.100 |
Why?
|
| Pancreatectomy | 1 | 2013 | 146 | 0.100 |
Why?
|
| Warm Ischemia | 1 | 2013 | 31 | 0.090 |
Why?
|
| Bilirubin | 1 | 2013 | 126 | 0.090 |
Why?
|
| Abdomen | 1 | 2013 | 133 | 0.090 |
Why?
|
| Robotics | 1 | 2013 | 107 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2016 | 566 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 955 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2023 | 273 | 0.080 |
Why?
|
| Sarcoma | 1 | 2013 | 210 | 0.080 |
Why?
|
| Policy | 2 | 2023 | 35 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2021 | 104 | 0.080 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 991 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 229 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2016 | 1695 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2020 | 239 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2014 | 1075 | 0.070 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 147 | 0.070 |
Why?
|
| Anastomosis, Surgical | 2 | 2019 | 175 | 0.070 |
Why?
|
| Clinical Protocols | 2 | 2020 | 228 | 0.070 |
Why?
|
| New York City | 1 | 2008 | 64 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2009 | 359 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2023 | 812 | 0.060 |
Why?
|
| Neutrophils | 1 | 2009 | 372 | 0.060 |
Why?
|
| Program Development | 1 | 2008 | 185 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1256 | 0.060 |
Why?
|
| Primary Graft Dysfunction | 1 | 2025 | 41 | 0.050 |
Why?
|
| Biopsy | 2 | 2021 | 1252 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 1002 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 228 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1170 | 0.050 |
Why?
|
| Nitrates | 1 | 2022 | 33 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2021 | 6494 | 0.050 |
Why?
|
| Integrases | 1 | 2023 | 158 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 26 | 0.040 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 29 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 903 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2021 | 96 | 0.040 |
Why?
|
| Aspirin | 1 | 2022 | 216 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 321 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 155 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2020 | 52 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 244 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 213 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 112 | 0.040 |
Why?
|
| Public Opinion | 1 | 2020 | 63 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 295 | 0.040 |
Why?
|
| Transplantation, Heterotopic | 1 | 2019 | 19 | 0.040 |
Why?
|
| Renal Veins | 1 | 2019 | 33 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 291 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 803 | 0.040 |
Why?
|
| Anatomic Variation | 1 | 2019 | 2 | 0.040 |
Why?
|
| Neutropenia | 1 | 2020 | 205 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1483 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2019 | 111 | 0.040 |
Why?
|
| Tetrazoles | 1 | 2019 | 72 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 222 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 285 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2120 | 0.040 |
Why?
|
| Texas | 2 | 2018 | 3621 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 261 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 122 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 189 | 0.040 |
Why?
|
| Comorbidity | 1 | 2023 | 1600 | 0.040 |
Why?
|
| Imidazoles | 1 | 2019 | 222 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 168 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 810 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 773 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 866 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2019 | 210 | 0.030 |
Why?
|
| Brain Death | 1 | 2018 | 74 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 364 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1322 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 137 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2023 | 3454 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 141 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2568 | 0.030 |
Why?
|
| Aorta | 1 | 2019 | 529 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1169 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 990 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1810 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 393 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 269 | 0.020 |
Why?
|
| Los Angeles | 1 | 2012 | 17 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 120 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 121 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 113 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 319 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2016 | 794 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 265 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2009 | 15 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2010 | 42 | 0.020 |
Why?
|
| Portal System | 1 | 2009 | 35 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2009 | 67 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 21 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1231 | 0.020 |
Why?
|
| Veterans | 1 | 2021 | 1797 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1636 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 200 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2009 | 160 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 75 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 248 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 263 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1356 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2010 | 251 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 204 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2010 | 195 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 6177 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1151 | 0.020 |
Why?
|
| C-Peptide | 1 | 2006 | 107 | 0.010 |
Why?
|
| North America | 1 | 2006 | 256 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2009 | 1104 | 0.010 |
Why?
|
| Canada | 1 | 2006 | 327 | 0.010 |
Why?
|
| Insulin | 1 | 2009 | 1151 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3460 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 34374 | 0.000 |
Why?
|